Literature DB >> 3897371

Role of the L3T4-antigen in T cell activation. II. Inhibition of T cell activation by monoclonal anti-L3T4 antibodies in the absence of accessory cells.

P Wassmer, C Chan, L Lögdberg, E M Shevach.   

Abstract

We have used two monoclonal antibodies (Mab) to the L3T4 antigen to reexplore the role of this molecule in the process of T cell activation. Both Mab (Gk1.5 and 2B6) were capable of inhibiting Con A-induced IL 2 production by a number of antigen-specific T cell hybridomas in an assay system that was free of major histocompatibility complex (MHC) class II antigen-bearing cells. The inhibition produced by the anti-L3T4 Mab was specific, because other Mab to cell surface antigens expressed on the hybridomas were without inhibitory effects. These studies rule out the possibility that the mechanism of inhibition by anti-L3T4 in this model is mediated by blocking interaction of L3T4 with MHC class II products. Taken together, these results and those of other groups of investigators, are most compatible with a dual function for L3T4 in T cell activation. L3T4 might first interact with MHC class II molecules or other molecules on target or accessory cells; L3T4 would subsequently transmit a signal that would regulate the activation process. Mab to L3T4 might exert inhibitory effects at one or both of these steps.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3897371

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Pillars article: the CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. 1988.

Authors:  Christopher E Rudd; James M Trevillyan; Jai Dev Dasgupta; Linda L Wong; Stuart F Schlossman
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

2.  Structure of the mouse gene encoding CD4 and an unusual transcript in brain.

Authors:  S D Gorman; B Tourvieille; J R Parnes
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Anti-L3T4 antibody treatment suppresses hepatic granuloma formation and abrogates antigen-induced interleukin-2 production in Schistosoma mansoni infection.

Authors:  R C Mathew; D L Boros
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

4.  Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4.

Authors:  D Wofsy; W E Seaman
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

5.  Expression of L3T4 molecules on Lyt-2+, class II-restricted antigen-specific T suppressor lymphocytes.

Authors:  J Heuer; J Degwert; E Kölsch
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

6.  Characteristics of a T lymphocyte-enhancing Ab-specific monoclonal antibody. I. Genetic specificity and preferential enhancement of allogeneic reactions.

Authors:  A B Peck; A K Kimura
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

7.  Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4.

Authors:  M Benkirane; M Hirn; D Carrière; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Production of erythrocyte autoantibodies in NZB mice is inhibited by CD4 antibodies.

Authors:  G G Oliveira; P R Hutchings; I M Roitt; P M Lydyard
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

Review 9.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

10.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.